UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P384 Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S396-S397

2021

Volltextzugriff (PDF)

risks of translocating wildlife: Pathogenic infection with Theileria sp. and Elaeophora elaphi in an imported red deer

Veterinary parasitology, 2004-12, Vol.126 (4), p.387-395

2004

Volltextzugriff (PDF)

P337 Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i353-i354

2022

Volltextzugriff (PDF)

Continuous subcutaneous local anaesthetic infusion to the sternotomy incision following surgery

Journal of cardiothoracic and vascular anesthesia, 2018-08, Vol.32, p.S18

2018

Volltextzugriff (PDF)

P03-8 - Continuous subcutaneous local anaesthetic infusion to the sternotomy incision following surgery

Journal of cardiothoracic and vascular anesthesia, 2018-08, Vol.32, p.S18-S18

2018

Volltextzugriff (PDF)

P851 Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1580-i1580

2024

Volltextzugriff (PDF)

P329 Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S265-S266

2019

Volltextzugriff (PDF)

P431 Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S324-S324

2019

Volltextzugriff (PDF)

P387 Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S299-S299

2018

Volltextzugriff (PDF)

P342 Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA technique

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S366-S366

2021

Volltextzugriff (PDF)

P546 Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S387-S387

2019

Volltextzugriff (PDF)

P548 Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S466-S467

2020

Volltextzugriff (PDF)

Identification, genetic diversity and prevalence of Theileria and Babesia species in a sheep population from Northern Spain

International journal for parasitology, 2004-08, Vol.34 (9), p.1059-1067

2004

Volltextzugriff (PDF)

Detection and identification of equine Theileria and Babesia species by reverse line blotting: epidemiological survey and phylogenetic analysis

Veterinary parasitology, 2004-08, Vol.123 (1), p.41-54

2004

Volltextzugriff (PDF)

P607 Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S416-S416

2018

Volltextzugriff (PDF)

P475 Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S320-S320

2017

Volltextzugriff (PDF)

P633 Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S403-S404

2017

Volltextzugriff (PDF)

P503 Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice

Journal of Crohn's and colitis, 2017-02, Vol.11 (suppl_1), p.S335-S336

2017

Volltextzugriff (PDF)

Analysis by two-dimensional electrophoresis of protein expression in liver of rats treated with an anticholinesterasic compound

Toxicology letters, 2010-07, Vol.196, p.S268-S268

2010

Volltextzugriff (PDF)

Analysis by two-dimensional electrophoresis of protein expression in liver of cynomolgus monkeys treated with a new candidate drug under non-clinical development. An activity of the melius project

Toxicology letters, 2010-07, Vol.196, p.S216-S216

2010

Volltextzugriff (PDF)

Study of the different toxic responses in male and female rats after treatment with new anticholinesterasic drug through genomic and proteomic tools. An activity of the Melius project

Toxicology letters, 2010-07, Vol.196, p.S271-S271

2010

Volltextzugriff (PDF)

Integration of -omics data for evaluating hepatotoxic response of monkeys treated with a compound under development. An activity of Melius project

Toxicology letters, 2010-07, Vol.196, p.S269-S269

2010

Volltextzugriff (PDF)

The nitrate/nitrite ABC transporter of Phormidium laminosum: Phosphorylation state of NrtA is not involved in its substrate binding activity

Biochimica et biophysica acta, 2006-02, Vol.1760 (2), p.172-181

2006

Volltextzugriff (PDF)

The risks of translocating wildlifePathogenic infection with Theileria sp. and Elaeophora elaphi in an imported red deer

Veterinary parasitology, 2004-12, Vol.126 (4), p.387-395

2004

Volltextzugriff (PDF)

The risks of translocating wildlife

Veterinary parasitology, 2004-12, Vol.126 (4), p.387-395

2004

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Aktive Filter

ThemaHumans

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(77)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(77)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

P384 Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick

risks of translocating wildlife: Pathogenic infection with Theileria sp. and Elaeophora elaphi in an imported red deer

P337 Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum

Continuous subcutaneous local anaesthetic infusion to the sternotomy incision following surgery

P03-8 - Continuous subcutaneous local anaesthetic infusion to the sternotomy incision following surgery

P851 Therapeutic drug monitoring of infliximab and adalimumab versus clinical control during maintenance therapy in patients with Inflammatory Bowel Disease

P329 Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar

P431 Validation of a therapeutic drug monitoring test to measure the adalimumab biosimilar SB5 in comparison with the reference adalimumab

P387 Infliximab therapeutic drug monitoring test validated for measuring CT-P13 and SB2 biosimilars

P342 Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA technique

P546 Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease

P548 Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study

Identification, genetic diversity and prevalence of Theileria and Babesia species in a sheep population from Northern Spain

Detection and identification of equine Theileria and Babesia species by reverse line blotting: epidemiological survey and phylogenetic analysis

P607 Clinical outcomes and immunogenicity analysis over 6 months following a switch from originator infliximab (Remicade®) to the biosimilar SB2 (Flixabi®) in inflammatory bowel disease patients

P475 Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study

P633 Antibodies to infliximab in patients treated with either the reference biologic or the biosimilar CT-P13 show identical reactivity towards biosimilars CT-P13 and SB2 in inflammatory bowel disease

P503 Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice

Analysis by two-dimensional electrophoresis of protein expression in liver of rats treated with an anticholinesterasic compound

Analysis by two-dimensional electrophoresis of protein expression in liver of cynomolgus monkeys treated with a new candidate drug under non-clinical development. An activity of the melius project

Study of the different toxic responses in male and female rats after treatment with new anticholinesterasic drug through genomic and proteomic tools. An activity of the Melius project

Integration of -omics data for evaluating hepatotoxic response of monkeys treated with a compound under development. An activity of Melius project

The nitrate/nitrite ABC transporter of Phormidium laminosum: Phosphorylation state of NrtA is not involved in its substrate binding activity

The risks of translocating wildlifePathogenic infection with Theileria sp. and Elaeophora elaphi in an imported red deer

The risks of translocating wildlife

Aktive Filter

Suchergebnisse filtern